Akoumianaki Tonia, Kardassis Dimitris, Polioudaki Hara, Georgatos Spyros D, Theodoropoulos Panayiotis A
Department of Biochemistry, University of Crete, School of Medicine, 71 003 Heraklion, Greece.
J Cell Sci. 2009 Apr 15;122(Pt 8):1111-8. doi: 10.1242/jcs.043034. Epub 2009 Mar 19.
We have investigated the subcellular distribution and dynamics of soluble tubulin in unperturbed and transfected HeLa cells. Under normal culture conditions, endogenous alpha/beta tubulin is confined to the cytoplasm. However, when the soluble pool of subunits is elevated by combined cold-nocodazole treatment and when constitutive nuclear export is inhibited by leptomycin B, tubulin accumulates in the cell nucleus. Transfection assays and FRAP experiments reveal that GFP-tagged beta-tubulin shuttles between the cytoplasm and the cell nucleus. Nuclear import seems to occur by passive diffusion, whereas exit from the nucleus appears to rely on nuclear export signals (NESs). Several such motifs can be identified by sequence criteria along the beta-tubulin molecule and mutations in one of these (NES-1) cause a significant accumulation in the nuclear compartment. Under these conditions, the cells are arrested in the G0-G1 phase and eventually die, suggesting that soluble tubulin interferes with important nuclear functions. Consistent with this interpretation, soluble tubulin exhibits stoichiometric binding to recombinant, normally modified and hyper-phosphorylated/acetylated histone H3. Tubulin-bound H3 no longer interacts with heterochromatin protein 1 and lamin B receptor, which are known to form a ternary complex under in vitro conditions. Based on these observations, we suggest that nuclear accumulation of soluble tubulin is part of an intrinsic defense mechanism, which tends to limit cell proliferation under pathological conditions. This readily explains why nuclear tubulin has been detected so far only in cancer or in transformed cells, and why accumulation of this protein in the nucleus increases after treatment with chemotherapeutic agents.
我们研究了未受干扰和转染的HeLa细胞中可溶性微管蛋白的亚细胞分布和动态变化。在正常培养条件下,内源性α/β微管蛋白局限于细胞质中。然而,当通过联合冷处理和诺考达唑处理使亚基的可溶性池升高,并且当通过莱普霉素B抑制组成型核输出时,微管蛋白会在细胞核中积累。转染实验和荧光漂白恢复实验表明,绿色荧光蛋白标记的β-微管蛋白在细胞质和细胞核之间穿梭。核输入似乎是通过被动扩散发生的,而从细胞核输出似乎依赖于核输出信号(NESs)。沿着β-微管蛋白分子可以通过序列标准鉴定出几个这样的基序,其中一个基序(NES-1)中的突变会导致在核区室中显著积累。在这些条件下,细胞停滞在G0-G1期并最终死亡,这表明可溶性微管蛋白会干扰重要的核功能。与这种解释一致,可溶性微管蛋白与重组的、正常修饰的和过度磷酸化/乙酰化的组蛋白H3表现出化学计量结合。与微管蛋白结合的H3不再与异染色质蛋白1和核纤层蛋白B受体相互作用,已知它们在体外条件下会形成三元复合物。基于这些观察结果,我们认为可溶性微管蛋白的核积累是一种内在防御机制的一部分,这种机制在病理条件下倾向于限制细胞增殖。这很容易解释为什么到目前为止仅在癌症或转化细胞中检测到核微管蛋白,以及为什么用化疗药物处理后这种蛋白在细胞核中的积累会增加。